When was EVOQ Therapeutics founded?

EVOQ Therapeutics was founded in 2016 and raised its 1st funding round 3 years after it was founded.

Where is EVOQ Therapeutics located?

EVOQ Therapeutics is headquartered in Ann Arbor, United States.

Who is the current CEO of EVOQ Therapeutics?

William Brinkerhoff of EVOQ Therapeutics.

How many employees does EVOQ Therapeutics have?

As of May 31, 2026, the latest employee count at EVOQ Therapeutics is 13.

Is EVOQ Therapeutics a funded company?

EVOQ Therapeutics is a funded company, having raised an undisclosed amount across 5 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Nov 13, 2019.

When was the latest funding round of EVOQ Therapeutics?

EVOQ Therapeutics' latest funding was a $***** Grant (prize money) round on Jun 18, 2025, with participation from 1 investor.

Where does EVOQ Therapeutics rank among its competitors?

EVOQ Therapeutics ranks 675th amongst 3310 active competitors, of which 1137 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Moderna, which secured $590M in Jan, 2025.

Who are the top competitors of EVOQ Therapeutics?

EVOQ Therapeutics' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, EVOQ Therapeutics secured the most recent funding round in June, 2025.

EVOQ Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Company Details

EVOQ Therapeutics is developing nano-vaccines for cancer immunotherapy. The company's nanodisc technology is based on nanodiscs composed of phospholipids and structural peptides, can deliver tumour antigen peptides and adjuvants to lymphoid tissues and prolong antigen presentation.

Key Metrics

Founded Year

2016

Location

Ann Arbor, United States

Stage

Funding Raised

Latest Funding Round

Grant (prize money), Jun 18, 2025, $*****

Investors

ID Ventures & 7 more

Ranked

675^th among 3310 active competitors

Employee Count

13 as on May 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3072 more

View EVOQ Therapeutics' full profile

EVOQ Therapeutics has raised funding over 5 rounds. Its first funding round was on Nov 13, 2019. Its latest funding round was a Grant (prize money) round on Jun 18, 2025 for $*****. 1 investor participated in its latest round. EVOQ Therapeutics has 8 institutional investors.

Here is the list of recent funding rounds of EVOQ Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 18, 2025	4281975	Grant (prize money)	8248707	7399831	6002877	1505000
Aug 29, 2024	7293898	Grant (prize money)	9273783	1737173	8761887	NIH
Sep 20, 2023	2581435	Grant (prize money)	4165876	2284916	4539854	HHS

Access funding benchmarks and valuations. Sign up today!

View details of EVOQ Therapeutics's funding rounds and investors

The founders of EVOQ Therapeutics are William Brinkerhoff, James J Moon and Anna Schwendeman.

Here are the details of EVOQ Therapeutics' key team members:

William Brinkerhoff: Co-Founder & CEO of EVOQ Therapeutics.
Contact Info: 1 email address
James J Moon: Co-Founder & CSO of EVOQ Therapeutics.
Contact Info: 1 email address
Anna Schwendeman: Co-Founder of EVOQ Therapeutics.
Contact Info: 1 email address

View details of EVOQ Therapeutics's Founder profiles and Board Members

EVOQ Therapeutics' employee count trend

EVOQ Therapeutics has 13 employees as of May 26. Here is EVOQ Therapeutics's employee count trend over the years:

Employee count trend for EVOQ Therapeutics

Uncover EVOQ Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of EVOQ Therapeutics include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of EVOQ Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating human disease conditions	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
4th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
5th	Senti Biosciences 2016, San Francisco (United States), Public	Developer of cell-based therapies for cancer treatment	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
7th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
8th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
10th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 31 others	71/100
675th	EVOQ Therapeutics 2016, Ann Arbor (United States), Funding Raised	Nano-vaccines for cancer immunotherapy	-	ID Ventures, Michigan Rise & 6 others	49/100